Workflow
X @Bloomberg
Bloombergยท2025-07-21 15:35

Market Assessment - HC Wainwright analysts suggest Sarepta shares have zero value [1] - This assessment follows regulatory interactions that could lead to market withdrawal of Elevidys treatment [1] Regulatory Impact - US regulators' actions could result in the withdrawal of Sarepta's Elevidys treatment from the market [1]